Modulating immunity as a therapy for bacterial infections

Nature Reviews Microbiology

Volumn 10, Issue 4, 2012, Pages 243-254

  Hancock, Robert E W ^a   Nijnik, Anastasia ^b   Philpott, Dana J ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGATOLIMOD; ANTHRAX VACCINE; CADI 05; DIMS 0150; EA 230; ERITORAN; IC 31; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; IMX 942; LACTOFERRICIN[1-11]; LUIVAC; MIFAMURTIDE; MX 226; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; OMIGANAN; OPEBACAN; PEXIGANAN; PHOSPHORYL LIPID A; PMX 30063; PMX 60063; POLYPEPTIDE ANTIBIOTIC AGENT; PROBIOTIC AGENT; RESATORVID; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; WART VIRUS VACCINE; XOMA 629;

ADAPTIVE IMMUNITY; ANTHRAX; ANTIBACTERIAL ACTIVITY; ANTIGEN RECOGNITION; ANTIINFLAMMATORY ACTIVITY; B LYMPHOCYTE; BACTERIAL INFECTION; BACTERIAL SKIN DISEASE; BASAL CELL CARCINOMA; CATHETER INFECTION; CELLULAR IMMUNITY; CONDYLOMA ACUMINATUM; DIABETIC FOOT; ENDOTOXEMIA; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOTHERAPY; IMPETIGO; INFECTION PREVENTION; INFLAMMATION; INFLUENZA; INNATE IMMUNITY; KERATOSIS; KIDNEY FAILURE; LEPROSY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TISSUE INJURY; TUBERCULOSIS; ULCERATIVE COLITIS; UTERINE CERVIX CANCER;

ADJUVANTS, IMMUNOLOGIC; BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; IMMUNITY, INNATE; IMMUNOMODULATION; MOLECULAR TARGETED THERAPY; NOD SIGNALING ADAPTOR PROTEINS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

BACTERIA (MICROORGANISMS);

EID: 84858381864     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro2745     Document Type: Review

References (123)

1. Clark, I. A. The advent of the cytokine storm. Immunol. Cell Biol. 85, 271-273 (2007). (Pubitemid 46878938)
2. Ulevitch, R. J. Therapeutics targeting the innate immune system. Nature Rev. Immunol. 4, 512-520 (2004). (Pubitemid 38931766)
3. Hamill, P., Brown, K., Jenssen, H. & Hancock, R. E. Novel anti-infectives: is host defence the answer? Curr. Opin. Biotechnol. 19, 628-636 (2008).
4. Yang, Y. F. et al. Long-term efficacy of interferon α therapy on hepatitis B viral replication in patients with chronic hepatitis B: a meta-analysis. Antiviral Res. 85, 361-365 (2010).
5. Jiang, X. R. et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nature Rev. Drug Discov. 10, 101-111 (2011).
6. Scherer, A. & McLean, A. Mathematical models of vaccination. Br. Med. Bull. 62, 187-199 (2002). (Pubitemid 34832480)
7. Karin, M., Lawrence, T. & Nizet, V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124, 823-835 (2006). (Pubitemid 43261455)
8. Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 415, 389-395 (2002). (Pubitemid 34100944)
9. Fjell, C. D., Hiss, J. A., Hancock, R. E. W. & Schneider, G. Designing antimicrobial peptides: form follows function. Nature Rev Drug Discov 11, 37-51 (2011).
10. Trinchieri, G. & Sher, A. Cooperation of Toll-like receptor signals in innate immune defence. Nature Rev. Immunol. 7, 179-190 (2007).
11. Medzhitov, R., Preston-Hurlburt, P. & Janeway, C. A. Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394-397 (1997). (Pubitemid 27334820)
12. Poltorak, A. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085-2088 (1998). (Pubitemid 29001265)
13. Ferwerda, B. et al. Functional consequences of Toll-like receptor 4 polymorphisms. Mol. Med. 14, 346-352 (2008). (Pubitemid 351785708)
14. Hennessy, E. J., Parker, A. E. & O'Neill, L. A. Targeting Toll-like receptors: emerging therapeutics? Nature Rev. Drug Discov. 9, 293-307 (2010).
15. Zaheer, S. A. et al. Combined multidrug and Mycobacterium w vaccine therapy in patients with multibacillary leprosy. J. Infect. Dis. 167, 401-410 (1993). (Pubitemid 23036443)
16. Klinman, D. M., Xie, H. & Ivins, B. E. CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine. Ann. NY Acad. Sci. 1082, 137-150 (2006). (Pubitemid 44955459)
17. Pastorelli, L., Pizarro, T. T., Cominelli, F. & Vecchi, M. Emerging drugs for the treatment of ulcerative colitis. Expert Opin. Emerg. Drugs 14, 505-521 (2009).
18. Rozy, A. & Chorostowska-Wynimko, J. Bacterial immunostimulants- mechanism of action and clinical application in respiratory diseases. Pneumonol. Alergol. Pol. 76, 353-359 (2008).
19. Ruah, S. B., Ruah, C., van Aubel, A., Abel, S. & Elsasser, U. Efficacy of a polyvalent bacterial lysate in children with recurrent respiratory tract infections. Adv. Ther. 18, 151-162 (2001). (Pubitemid 33010375)
20. Dittmer, U. & Olbrich, A. R. Treatment of infectious diseases with immunostimulatory oligodeoxynucleotides containing CpG motifs. Curr. Opin. Microbiol. 6, 472-477 (2003). (Pubitemid 37345412)
21. Evans, S. E. et al. Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am. J. Respir. Cell Mol. Biol. 42, 40-50 (2009).
22. Munoz, N. et al. Mucosal administration of flagellin protects mice from Streptococcus pneumoniae lung infection. Infect. Immun. 78, 4226-4233 (2010).
23. Yu, F. S. et al. Flagellin stimulates protective lung mucosal immunity: role of cathelicidin-related antimicrobial peptide. J. Immunol. 185, 1142-1149 (2010).
24. Kinnebrew, M. A. et al. Bacterial flagellin stimulates Toll-like receptor 5-dependent defense against vancomycin-resistant Enterococcus infection. J. Infect. Dis. 201, 534-543 (2010).
25. Clement, C. G. et al. Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am. J. Respir. Crit. Care Med. 177, 1322-1330 (2008). (Pubitemid 351860909)
26. Ireland, R. et al. Effective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigens. PLoS Pathog. 6, e1000921 (2010).
27. Tuvim, M. J., Evans, S. E., Clement, C. G., Dickey, B. F. & Gilbert, B. E. Augmented lung inflammation protects against influenza A pneumonia. PLoS ONE 4, e4176 (2009).
28. Shinya, K. et al. Toll-like receptor pre-stimulation protects mice against lethal infection with highly pathogenic influenza viruses. Virol. J. 8, 97 (2011).
29. Antonelli, L. R. et al. Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J. Clin. Invest. 120, 1674-1682 (2010).
30. Hotchkiss, R. S. & Karl, I. E. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348, 138-150 (2003). (Pubitemid 36056721)
31. Rice, T. W. et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit. Care Med. 38, 1685-1694 (2010).
32. Tidswell, M. et al. Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis. Crit. Care Med. 38, 72-83 (2010).
33. Barochia, A., Solomon, S., Cui, X., Natanson, C. & Eichacker, P. Q. Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opin. Drug Metab. Toxicol. 7, 479-494 (2011).
34. Ungaro, R. et al. A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G1167-G1179 (2009).
35. Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S. & Medzhitov, R. Recognition of commensal microflora by Toll-like receptors is required for intestinal homeostasis. Cell 118, 229-241 (2004). (Pubitemid 38962578)
36. Abreu, M. T. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nature Rev. Immunol. 10, 131-144 (2010).
37. Dupaul-Chicoine, J. et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 32, 367-378 (2010).
38. Zaph, C. et al. Epithelial-cell-intrinsic IKK-β expression regulates intestinal immune homeostasis. Nature 446, 552-556 (2007). (Pubitemid 46514719)
39. Werts, C., Rubino, S., Ling, A., Girardin, S. E. & Philpott, D. J. Nod-like receptors in intestinal homeostasis, inflammation, and cancer. J. Leukoc. Biol. 90, 471-482 (2011).
40. Sorbara, M. & Philpott, D. Peptidoglycan: a critical activator of the mammalian immune system during infection and homeostasis. Immunol. Rev. 243, 40-60 (2011).
41. Leemans, J. C., Cassel, S. L. & Sutterwala, F. S. Sensing damage by the NLRP3 inflammasome. Immunol. Rev. 243, 152-162 (2011).
42. Spreafico, R., Ricciardi-Castagnoli, P. & Mortellaro, A. The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants. Eur. J. Immunol. 40, 638-642 (2010).
43. Girardin, S. E. et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278, 8869-8872 (2003). (Pubitemid 36800360)
44. Inohara, N. et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J. Biol. Chem. 278, 5509-5512 (2003). (Pubitemid 36800790)
45. Chedid, L., Audibert, F. & Johnson, A. G. Biological activities of muramyl dipeptide, a synthetic glycopeptide analogous to bacterial immunoregulating agents. Prog. Allergy 25, 63-105 (1978). (Pubitemid 9012043)
46. Fritz, J. H., et al. Nod1-mediated innate immune recognition of peptidoglycan contributes to the onset of adaptive immunity. Immunity 26, 445-459 (2007). (Pubitemid 46604867)
47. Magalhaes, J. G. et al. Nucleotide oligomerization domain-containing proteins instruct T cell helper type 2 immunity through stromal activation. Proc. Natl Acad. Sci. USA 108, 14896-14901 (2011).
48. O'Hagan, D. T. & De Gregorio, E. The path to a successful vaccine adjuvant-'the long and winding road'. Drug Discov. Today 14, 541-551 (2009).
49. Bahr, G. M. Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunodulator murabutide. J. Antimicrob. Chemother. 51, 5-8 (2003). (Pubitemid 36163820)
50. Mine, Y. et al. Immunoactive peptides, FK-156 and FK-565. I. Enhancement of host resistance to microbial infection in mice. J. Antibiot. (Tokyo) 36, 1045-1050 (1983). (Pubitemid 13046930)
51. Wardowska, A. et al. Analogues of muramyl dipeptide (MDP) and tuftsin limit infection and inflammation in murine model of sepsis. Vaccine 27, 369-374 (2009).
52. Geddes, K., Magalhaes, J. G. & Girardin, S. E. Unleashing the therapeutic potential of NOD-like receptors. Nature Rev. Drug Discov. 8, 465-479 (2009).
53. Fukushima, A. et al. Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus. Vaccine 14, 485-491 (1996). (Pubitemid 26173750)
54. Sarkar, K. & Das, P. K. Protective effect of neoglycoprotein- conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines. J. Immunol. 158, 5357-5365 (1997). (Pubitemid 127681242)
55. Le Bourhis, L. et al. Role of Nod1 in mucosal dendritic cells during Salmonella pathogenicity island 1-independent Salmonella enterica serovar Typhimurium infection. Infect. Immun. 77, 4480-4486 (2009).
56. O'Reilly, T. & Zak, O. Enhancement of the effectiveness of antimicrobial therapy by muramyl peptide immunomodulators. Clin. Infect. Dis. 14, 1100-1109 (1992).
57. Kim, Y. G. et al. Viral infection augments Nod1/2 signaling to potentiate lethality associated with secondary bacterial infections. Cell Host Microbe 9, 496-507 (2011).
58. Argast, G. M., Fausto, N. & Campbell, J. S. Inhibition of RIP2/RICK/CARDIAK activity by pyridinyl imidazole inhibitors of p38 MAPK. Mol. Cell. Biochem. 268, 129-140 (2005). (Pubitemid 40287835)
59. Hancock, R. E. & Sahl, H. G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nature Biotech. 24, 1551-1557 (2006). (Pubitemid 44967479)
60. Nizet, V. et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 414, 454-457 (2001). (Pubitemid 34173727)
61. Ong, P. Y. et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347, 1151-1160 (2002).
62. Nijnik, A., Pistolic, J., Wyatt, A., Tam, S. & Hancock, R. E. Human cathelicidin peptide LL-37 modulates the effects of IFN-γ on APCs. J. Immunol. 183, 5788-5798 (2009).
63. Scott, M. G. et al. An anti-infective peptide that selectively modulates the innate immune response. Nature Biotech. 25, 465-472 (2007). (Pubitemid 46572850)
64. Overhage, J. et al. The human host defence peptide LL-37 prevents bacterial biofilm formation. Infect Immun. 76, 4176-4182 (2008).
65. Carretero, M. et al. In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37. J. Invest. Dermatol. 128, 223-236 (2008). (Pubitemid 350249392)
66. Hirsch, T. et al. Human beta-defensin-3 promotes wound healing in infected diabetic wounds. J. Gene Med. 11, 220-228 (2009).
67. Easton, D. M., Nijnik, A., Mayer, M. L. & Hancock, R. E. Potential of immunomodulatory host defense peptides as novel anti-infectives. Trends Biotechnol. 27, 582-590 (2009).
68. Karaolis, D. K. et al. 3′,5′-cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation. Biochem. Biophys. Res. Commun. 329, 40-45 (2005). (Pubitemid 40255417)
69. Brouillette, E., Hyodo, M., Hayakawa, Y., Karaolis, D. K. & Malouin, F. 3′,5′-cyclic diguanylic acid reduces the virulence of biofilm-forming Staphylococcus aureus strains in a mouse model of mastitis infection. Antimicrob. Agents Chemother. 49, 3109-3113 (2005). (Pubitemid 41060547)
70. Karaolis, D. K. et al. Bacterial c-di-GMP is an immunostimulatory molecule. J. Immunol. 178, 2171-2181 (2007). (Pubitemid 46233415)
71. Chen, W., Kuolee, R. & Yan, H. The potential of 3′,5′- cyclic diguanylic acid (c-di-GMP) as an effective vaccine adjuvant. Vaccine 28, 3080-3085 (2010).
72. Ebensen, T. et al. Bis-(3′,5′)-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant. Vaccine 29, 5210-5220 (2011).
73. Burdette, D. L. et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature 478, 515-518 (2011).
74. Sauer, J. D. et al. The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect. Immun. 79, 688-694 (2011).
75. Woodward, J. J., Iavarone, A. T. & Portnoy, D. A. c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response. Science 328, 1703-1705 (2010).
76. Camilli, A. & Bassler, B. L. Bacterial small-molecule signaling pathways. Science 311, 1113-1116 (2006).
77. Smith, R. S., Harris, S. G., Phipps, R. & Iglewski, B. The Pseudomonas aeruginosa quorum-sensing molecule N-(3-oxododecanoyl)homoserine lactone contributes to virulence and induces inflammation in vivo. J. Bacteriol. 184, 1132-1139 (2002). (Pubitemid 34113382)
78. Teplitski, M., Mathesius, U. & Rumbaugh, K. P. Perception and degradation of N-acyl homoserine lactone quorum sensing signals by mammalian and plant cells. Chem. Rev. 111, 100-116 (2011).
79. Mayer, M. L., Sheridan, J. A., Blohmke, C. J., Turvey, S. E. & Hancock, R. E. The Pseudomonas aeruginosa autoinducer 3O-C12 homoserine lactone provokes hyperinflammatory responses from cystic fibrosis airway epithelial cells. PLoS ONE 6, e16246 (2011).
80. Khajanchi, B. K., Kirtley, M. L., Brackman, S. M. & Chopra, A. K. Immunomodulatory and protective roles of quorum-sensing signaling molecules N-acyl homoserine lactones during infection of mice with Aeromonas hydrophila. Infect. Immun. 79, 2646-2657 (2011).
81. Mattmann, M. E. & Blackwell, H. E. Small molecules that modulate quorum sensing and control virulence in Pseudomonas aeruginosa. J. Org. Chem. 75, 6737-6746 (2010).
82. Miyairi, S. et al. Immunization with 3-oxododecanoyl-l-homoserine lactone-protein conjugate protects mice from lethal Pseudomonas aeruginosa lung infection. J. Med. Microbiol. 55, 1381-1387 (2006). (Pubitemid 44651665)
83. Wu, H. et al. Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J. Antimicrob. Chemother. 53, 1054-1061 (2004). (Pubitemid 38807648)
84. Smyth, A. R. et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis-a pilot randomized controlled trial. Pediatr. Pulmonol. 45, 356-362 (2010).
85. Brackman, G., Cos, P., Maes, L., Nelis, H. J. & Coenye, T. Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo. Antimicrob. Agents Chemother. 55, 2655-2661 (2011).
86. Gardy, J. L., Lynn, D. J., Brinkman, F. S. & Hancock, R. E. Enabling a systems biology approach to immunology: focus on innate immunity. Trends Immunol. 30, 249-262 (2009).
87. Park, B. S. et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458, 1191-1195 (2009).
88. Jin, M. S. et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130, 1071-1082 (2007). (Pubitemid 47410281)
89. Choe, J., Kelker, M. S. & Wilson, I. A. Crystal structure of human Toll-like receptor 3 (TLR3) ectodomain. Science 309, 581-585 (2005). (Pubitemid 41033635)
90. Gavin, A. L. et al. Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science 314, 1936-1938 (2006). (Pubitemid 46026117)
91. Kasturi, S. P. et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470, 543-547 (2011).
92. Guy, B. The perfect mix: recent progress in adjuvant research. Nature Rev. Microbiol. 5, 505-517 (2007). (Pubitemid 46925379)
93. Biswas, S. K. & Lopez-Collazo, E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 30, 475-487 (2009).
94. Schellack, C. et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 24, 5461-5472 (2006). (Pubitemid 43831376)
95. van Dissel, J. T. et al. Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine 29, 2100-2109 (2011).
96. Hilpert, K., Volkmer-Engert, R., Walter, T. & Hancock, R. E. High-throughput generation of small antibacterial peptides with improved activity. Nature Biotech. 23, 1008-1012 (2005). (Pubitemid 41114036)
97. Jenssen, H., Fjell, C. D., Cherkasov, A. & Hancock, R. E. QSAR modeling and computer-aided design of antimicrobial peptides. J. Pept. Sci. 14, 110-114 (2008). (Pubitemid 351188097)
98. Loose, C., Jensen, K., Rigoutsos, I. & Stephanopoulos, G. A linguistic model for the rational design of antimicrobial peptides. Nature 443, 867-869 (2006). (Pubitemid 44622698)
99. Braff, M. H. et al. Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. J. Immunol. 174, 4271-4278 (2005). (Pubitemid 40396008)
100. Nijnik, A. et al. Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. J. Immunol. 184, 2539-2550 (2010).
101. Fischer, P. M. The design, synthesis and application of stereochemical and directional peptide isomers: a critical review. Curr. Protein Pept. Sci. 4, 339-356 (2003). (Pubitemid 37236348)
102. Lande, R. et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449, 564-569 (2007). (Pubitemid 47525141)
103. Kindrachuk, J. et al. A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. Vaccine 27, 4662-4671 (2009).
104. Martineau, A. R. et al. High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 377, 242-250 (2011).
105. Liu, P. T. et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311, 1770-1773 (2006).
106. Raqib, R. et al. Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proc. Natl Acad. Sci. USA 103, 9178-9183 (2006). (Pubitemid 43902552)
107. Medzhitov, R. Recognition of microorganisms and activation of the immune response. Nature 449, 819-826 (2007). (Pubitemid 47598622)
108. Kumar, H., Kawai, T. & Akira, S. Pathogen recognition by the innate immune system. Int. Rev. Immunol. 30, 16-34 (2009).
109. Lambrecht, B. N., Kool, M., Willart, M. A. & Hammad, H. Mechanism of action of clinically approved adjuvants. Curr. Opin. Immunol. 21, 23-29 (2009).
110. Nicholls, E. F., Madera, L. & Hancock, R. E. Immunomodulators as adjuvants for vaccines and antimicrobial therapy. Ann. NY Acad. Sci. 1213, 46-61 (2011).
111. Round, J. L. & Mazmanian, S. K. The gut microbiota shapes intestinal immune responses during health and disease. Nature Rev. Immunol. 9, 313-323 (2009).
112. Willing, B. P., Russell, S. L. & Finlay, B. B. Shifting the balance: antibiotic effects on host-microbiota mutualism. Nature Rev. Microbiol. 9, 233-243 (2011).
113. Lebeer, S., Vanderleyden, J. & De Keersmaecker, S. C. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nature Rev. Microbiol. 8, 171-184 (2010).
114. Schlee, M. et al. Probiotic lactobacilli and VSL#3 induce enterocyte β-defensin 2. Clin. Exp. Immunol. 151, 528-535 (2008). (Pubitemid 351160737)
115. Schlee, M. et al. Induction of human β-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect. Immun. 75, 2399-2407 (2007). (Pubitemid 46744330)
116. Cosseau, C. et al. The commensal Streptococcus salivarius K12 downregulates the innate immune responses of human epithelial cells and promotes host-microbe homeostasis. Infect. Immun. 76, 4163-4175 (2008).
117. Hafez, M. et al. The K5 capsule of Escherichia coli strain Nissle 1917 is important in mediating interactions with intestinal epithelial cells and chemokine induction. Infect. Immun. 77, 2995-3003 (2009).
118. Senok, A. C., Verstraelen, H., Temmerman, M. & Botta, G. A. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst. Rev. 4, CD006289 (2009).
119. Twetman, S. & Stecksen-Blicks, C. Probiotics and oral health effects in children. Int. J. Paediatr. Dent. 18, 3-10 (2008).
120. Wells, J. M. & Mercenier, A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nature Rev. Microbiol. 6, 349-362 (2008). (Pubitemid 351552656)
121. Gaspari, A., Tyring, S. K. & Rosen, T. Beyond a decade of 5% imiquimod topical therapy. J. Drugs Dermatol. 8, 467-474 (2009).
122. Harper, D. M. et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367, 1247-1255 (2006).
123. Dubensky, T. W. Jr & Reed, S. G. Adjuvants for cancer vaccines. Semin. Immunol. 22, 155-161 (2010).